Page 89 - GTM-3-4

Global Translational Medicine Blood parameters for SCLC and AC relapse prognosis

Blood cell receptors CXCR1, CXCR2, and CD44v6 from patients with other TNM descriptors (T1N2M0,
were determined using a Navios flow cytometer (Beckman T3N1M0, T2N2M0, T4N0M0, and T3N2M0). In patients
Coulter, USA). 13 with T4N1M0 (stage IIIA AC), the relapse-free survival
after treatment is lower than in patients with other T and N
2.4. Statistical analysis
variants of Stage IIIA. In addition, patients with T3N2M0
The dependence of the relapse-free period duration on (stage IIIB) experience slower disease relapses than the
the observation time was assessed using Kaplan-Meier other T and N variants within the same stage. According to
graphs. Single and multivariate Cox proportional hazard the Kaplan-Meier graph (Figure 1A and C), the relapse-free
models were used to analyze the relationship between survival of patients 1 year after treatment can be divided
the determined laboratory parameters and survival. into two groups. One is characterized by a relatively high
Comparison of groups with different risks of NSCLC survival rate, includes patients with T1N2M0, T3N1M0,
relapse was performed using the Log-Rank test. The data T2N2M0, T4N0M0, and T3N2M0. The other group
analysis included non-parametric statistics methods typically with a shorter relapse-free period includes
(MedCalc Software, Belgium). Differences in the values patients with T4N1M0 and T4N2M0. The difference in
of the determined parameters between groups of patients survival between these groups is statistically significant,
were evaluated using Mann–Whitney U-test. The overall as indicated by the results of the Log-Rank test (Figure 1B
prognostic value of the laboratory tests was assessed by and D). The χ value for differences in relapse-free survival
2
constructing receiver operating characteristic (ROC) between risk groups based on TNM stratification for
curves, followed by calculating the area under the ROC patients with operable Stage III SCLC is 10.25 (P = 0.017),
curve (AUC). Statistical significance was defined as
34
P < 0.05. and for patients with AC, it is 10.31 (P = 0.025).
We compared several blood laboratory parameters
3. Results between the two risk groups of relapse-free survival for
Kaplan-Meier graphs show that the relapse-free survival of Stage III SCLC patients (Table 3). Only the proportion of
patients with tumor descriptors T4N1M0 and T4N2M0 in lymphocytes with the CXCR1 receptor, monocytes with
SCLC (Figure 1A) and AC (Figure 1C) differs significantly the CXCR2 receptor, and the CYFRA 21-1 level showed

A B

C D

Figure 1. Relapse-free survival of patients with Stage III squamous cell lung cancer (A and B) and adenocarcinoma (C and D), stratified by the TNM
classifications over the course of 12 months after the treatment.

Volume 3 Issue 4 (2024) 5 doi: 10.36922/gtm.4865